Marbury Partner Michelle O’Brien and Senior Partner, Tom Irving, will be participating on a panel in the Strafford webinar entitled “Inducement in a Pharmaceutical, Post-Launch Non-Hatch-Waxman World: Evaluating the Effect of a Skinny Label, Implications of GSK v. Teva”.

Michelle and Tom will be discussing the following cases:

  1. Amarin Pharma v. Hikma Pharms. USA Inc., No. 20-1630 (D. Del.), including the status of the Federal Circuit Appeal lodged by Amarin;
  2. The Federal Circuit opinion in Genentech v. Sandoz, 55 F.4th 1368 (Fed. Cir. 2022);  and
  3. Lundbeck v. Lupin, No. 18-00088 (D. Del., Stark), on appeal (No. 22-1246, response filed Jan. 17, 2023), including its pending spirited appeal at the Federal Circuit.

 

They will also be discussing post-launch issues for both Branded and Generic pharmaceutical companies.  Link here.